PX-12 Inhibits NLRP3 Inflammasome Activation to Treat Psoriasis

April 2023 in “ Journal of Investigative Dermatology ”

T. Hwang, K. Chen

PX-12 NLRP3 inflammasome psoriasis 1-methylpropyl 2-imidazolyl disulfide imiquimod IL-1β IL-18 pyroptotic cell death lipopolysaccharide THP-1 macrophages nigericin monosodium urate reactive oxygen species caspase-1 potassium lysosome damage NLRP3 IMQ IL-1 beta ROS LPS

Studysummary This study found that PX-12 inhibited the NLRP3 inflammasome and reduced psoriasis-like symptoms in a mouse model, suggesting its potential as a treatment for psoriasis.

Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer ·

Read the full study on jidonline.org →

Discuss this study in the Community →

Similar research 5

Targeting Anti-Inflammatory Immunonanocarriers to Human and Murine Neutrophils via Ly6 Antigen for Psoriasiform Dermatitis Alleviation Journal of Investigative Dermatology · 2023
An Innovative Phase 1b Trial Demonstrating Proof-of-Pharmacology for Two Novel IRAK4-Inhibitors Using a Local and Systemic Driven Immune Response Journal of Investigative Dermatology · 2023
Small Molecule Wnt Pathway Inhibitor (SM04755) as a Potential Topical Psoriasis Treatment Journal of Investigative Dermatology · 2017
Real-World Single-Center Experience With 10 Cases of Generalized Pustular Psoriasis Successfully Treated With Ixekizumab Journal of the American Academy of Dermatology · 2019
Monovalent Antibody-Conjugated Lipid-Polymer Nanohybrids for Active Targeting to Desmoglein 3 of Keratinocytes to Attenuate Psoriasiform Inflammation Theranostics · 2021

Related Community Posts Join

6 / 1000+ results

community PG causing irritation when applying RU

in Research/Science 3 years ago

The user is experiencing irritation from using PG with RU58841 and is seeking alternative solutions like K&B in the UK. They report redness, itchiness, and flaky skin from the current treatment.

community 12 months progress. Min Topical Fin Pyri MN

15 upvotes 2 years ago

A user shared their 12-month progress using 0.5% Pyrilutamide once daily, 0.025% topical finasteride once daily, 5% Minoxidil twice daily, and microneedling 3 times a week. They reported good progress but noted a slowdown in recent months, hoping for thicker hair soon.

community Anyone have an alternative solvent for pyrilutamide??

in Product 2 upvotes 2 years ago

The user is seeking an alternative solvent for pyrilutamide due to skin irritation from ethanol and propylene glycol. They experienced similar issues with topical minoxidil.

community What is everyone's assessment of pyrilutamide 1.0% topical as a adjunct treatment?

5 upvotes 3 months ago

The conversation discusses the use of pyrilutamide as an adjunct treatment for hair loss, particularly for those already using finasteride and minoxidil. Users share mixed experiences, with some reporting side effects like numbness and gynecomastia, while others note its potential benefits in reducing shedding and scalp itchiness.

community Pyrludimide (KX-826) actual drug could work better than the cosmetic version

10 upvotes 2 months ago

The conversation discusses the effectiveness of different versions of Pyrilutamide (KX-826) for hair loss, with skepticism about the cosmetic versions and interest in a new 1.0% version. Some users report success with products from Koshine, while others criticize Pyrilutamide's effectiveness compared to Minoxidil.

community Hair Loss “Cure” for Inflammation: Topical Roflumilast

in Research/Science 32 upvotes 8 months ago

Topical roflumilast is effective for reducing inflammation in various scalp conditions like seborrheic dermatitis, psoriasis, and eczema, but not proven to stop scarring alopecia. Alternatives like apremilast and Vtama are also discussed for their anti-inflammatory benefits.